+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Osteosarcoma - Pipeline Review, H1 2019

  • ID: 4769187
  • Drug Pipelines
  • 625 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Aadi Bioscience Inc
  • Boehringer Ingelheim GmbH
  • Eisai Co Ltd
  • Kitov Pharma Ltd
  • Nektar Therapeutics
  • Sorrento Therapeutics Inc
  • MORE
Osteosarcoma - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H1 2019, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights

This latest pipeline guide Osteosarcoma - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 31, 7, 1, 26 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 4, 3 and 3 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aadi Bioscience Inc
  • Boehringer Ingelheim GmbH
  • Eisai Co Ltd
  • Kitov Pharma Ltd
  • Nektar Therapeutics
  • Sorrento Therapeutics Inc
  • MORE
Introduction

Osteosarcoma - Overview

Osteosarcoma - Therapeutics Development

Osteosarcoma - Therapeutics Assessment

Osteosarcoma - Companies Involved in Therapeutics Development

Osteosarcoma - Drug Profiles

Osteosarcoma - Dormant Projects

Osteosarcoma - Discontinued Products

Osteosarcoma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Osteosarcoma, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Osteosarcoma - Pipeline by Aadi Bioscience Inc, H1 2019

Osteosarcoma - Pipeline by Advanced BioDesign, H1 2019

Osteosarcoma - Pipeline by Advenchen Laboratories LLC, H1 2019

Osteosarcoma - Pipeline by Amgen Inc, H1 2019

Osteosarcoma - Pipeline by AntiCancer Inc, H1 2019

Osteosarcoma - Pipeline by APEIRON Biologics AG, H1 2019

Osteosarcoma - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2019

Osteosarcoma - Pipeline by Autolus Therapeutics Plc, H1 2019

Osteosarcoma - Pipeline by Bayer AG, H1 2019

Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2019

Osteosarcoma - Pipeline by BioMed Valley Discoveries Inc, H1 2019

Osteosarcoma - Pipeline by Boehringer Ingelheim GmbH, H1 2019

Osteosarcoma - Pipeline by Bristol-Myers Squibb Co, H1 2019

Osteosarcoma - Pipeline by Celgene Corp, H1 2019

Osteosarcoma - Pipeline by Cellectar Biosciences Inc, H1 2019

Osteosarcoma - Pipeline by Cellestia Biotech AG, H1 2019

Osteosarcoma - Pipeline by Cellmid Ltd, H1 2019

Osteosarcoma - Pipeline by CorMedix Inc, H1 2019

Osteosarcoma - Pipeline by Eisai Co Ltd, H1 2019

Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H1 2019

Osteosarcoma - Pipeline by Endocyte Inc, H1 2019

Osteosarcoma - Pipeline by Exelixis Inc, H1 2019

Osteosarcoma - Pipeline by GlycoMimetics Inc, H1 2019

Osteosarcoma - Pipeline by Intezyne Inc, H1 2019

Osteosarcoma - Pipeline by Iovance Biotherapeutics Inc, H1 2019

Osteosarcoma - Pipeline by Ipsen SA, H1 2019

Osteosarcoma - Pipeline by Isofol Medical AB, H1 2019

Osteosarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2019

Osteosarcoma - Pipeline by Kitov Pharma Ltd, H1 2019

Osteosarcoma - Pipeline by MacroGenics Inc, H1 2019

Osteosarcoma - Pipeline by Mateon Therapeutics Inc, H1 2019

List of Figures

Number of Products under Development for Osteosarcoma, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aadi Bioscience Inc
  • Advanced BioDesign
  • Advenchen Laboratories LLC
  • Amgen Inc
  • AntiCancer Inc
  • APEIRON Biologics AG
  • Arrowhead Pharmaceuticals Inc
  • Autolus Therapeutics Plc
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • BioMed Valley Discoveries Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Cellectar Biosciences Inc
  • Cellestia Biotech AG
  • Cellmid Ltd
  • CorMedix Inc
  • Eisai Co Ltd
  • Eleison Pharmaceuticals LLC
  • Endocyte Inc
  • Exelixis Inc
  • GlycoMimetics Inc
  • Intezyne Inc
  • Iovance Biotherapeutics Inc
  • Ipsen SA
  • Isofol Medical AB
  • Jiangsu Hengrui Medicine Co Ltd
  • Kitov Pharma Ltd
  • MacroGenics Inc
  • Mateon Therapeutics Inc
  • MD Biosciences GmbH
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Nektar Therapeutics
  • Nkarta Inc
  • Novartis AG
  • Oncolix Inc
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • Provectus Biopharmaceuticals Inc
  • Scancell Holdings Plc
  • Sorrento Therapeutics Inc
  • Teijin Pharma Ltd
  • Tyme Technologies Inc
  • United Therapeutics Corp
  • Vaccinex Inc
  • VCN Biosciences SL
  • Y-mAbs Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4769187
Adroll
adroll